HALO Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 44.59% compared to Halozyme Therapeutics's net margin of 23.32%. Halozyme Therapeutics's return on equity of 137.42% beat Johnson & Johnson's return on equity of 30.18%.

Halozyme Therapeutics has a consensus price target of $65.89, signalling upside risk potential of 13.58%. On the other hand Johnson & Johnson has an analysts' consensus of $170.92 which suggests that it could grow by 3.36%. Given that Halozyme Therapeutics has higher upside potential than Johnson & Johnson, analysts believe Halozyme Therapeutics is more attractive than Johnson & Johnson.

Halozyme Therapeutics has a beta of 1.146, which suggesting that the stock is 14.574% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.579%.

Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.05% to investors and pays a quarterly dividend of $1.30 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics quarterly revenues are $264.9M, which are smaller than Johnson & Johnson quarterly revenues of $23.7B. Halozyme Therapeutics's net income of $118.1M is lower than Johnson & Johnson's net income of $5.5B. Notably, Halozyme Therapeutics's price-to-earnings ratio is 15.43x while Johnson & Johnson's PE ratio is 17.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.89x versus 4.41x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 44.59% compared to Halozyme Therapeutics's net margin of 32.71%. Halozyme Therapeutics's return on equity of 137.42% beat Merck &'s return on equity of 39.02%.

Halozyme Therapeutics has a consensus price target of $65.89, signalling upside risk potential of 13.58%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 23.48%. Given that Merck & has higher upside potential than Halozyme Therapeutics, analysts believe Merck & is more attractive than Halozyme Therapeutics.

Halozyme Therapeutics has a beta of 1.146, which suggesting that the stock is 14.574% more volatile than S&P 500. In comparison Merck & has a beta of 0.389, suggesting its less volatile than the S&P 500 by 61.063%.

Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.88% to investors and pays a quarterly dividend of $0.81 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics quarterly revenues are $264.9M, which are smaller than Merck & quarterly revenues of $15.5B. Halozyme Therapeutics's net income of $118.1M is lower than Merck &'s net income of $5.1B. Notably, Halozyme Therapeutics's price-to-earnings ratio is 15.43x while Merck &'s PE ratio is 12.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.89x versus 3.27x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 44.59% compared to Halozyme Therapeutics's net margin of 6.22%. Halozyme Therapeutics's return on equity of 137.42% beat Insulet's return on equity of 36.9%.

Halozyme Therapeutics has a consensus price target of $65.89, signalling upside risk potential of 13.58%. On the other hand Insulet has an analysts' consensus of $336.85 which suggests that it could grow by 16.85%. Given that Insulet has higher upside potential than Halozyme Therapeutics, analysts believe Insulet is more attractive than Halozyme Therapeutics.

Halozyme Therapeutics has a beta of 1.146, which suggesting that the stock is 14.574% more volatile than S&P 500. In comparison Insulet has a beta of 1.346, suggesting its more volatile than the S&P 500 by 34.619%.

Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Halozyme Therapeutics quarterly revenues are $264.9M, which are smaller than Insulet quarterly revenues of $569M. Halozyme Therapeutics's net income of $118.1M is higher than Insulet's net income of $35.4M. Notably, Halozyme Therapeutics's price-to-earnings ratio is 15.43x while Insulet's PE ratio is 51.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.89x versus 9.70x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

AVITA Medical has a net margin of 44.59% compared to Halozyme Therapeutics's net margin of -74.86%. Halozyme Therapeutics's return on equity of 137.42% beat AVITA Medical's return on equity of -415.55%.

Halozyme Therapeutics has a consensus price target of $65.89, signalling upside risk potential of 13.58%. On the other hand AVITA Medical has an analysts' consensus of $16.95 which suggests that it could grow by 217.12%. Given that AVITA Medical has higher upside potential than Halozyme Therapeutics, analysts believe AVITA Medical is more attractive than Halozyme Therapeutics.

Halozyme Therapeutics has a beta of 1.146, which suggesting that the stock is 14.574% more volatile than S&P 500. In comparison AVITA Medical has a beta of 1.518, suggesting its more volatile than the S&P 500 by 51.797%.

Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AVITA Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. AVITA Medical pays out -- of its earnings as a dividend.

Halozyme Therapeutics quarterly revenues are $264.9M, which are larger than AVITA Medical quarterly revenues of $18.5M. Halozyme Therapeutics's net income of $118.1M is higher than AVITA Medical's net income of -$13.9M. Notably, Halozyme Therapeutics's price-to-earnings ratio is 15.43x while AVITA Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.89x versus 1.94x for AVITA Medical. Usually stocks with elevated PS ratios are considered overvalued.